Thanh Nhat Pham

Dr. Thanh Nhat Pham

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2019 in Medicinal Research Reviews
Verified
Journal Article
Closed access
PDF file
Thanh Nhat PhamThanh Nhat Pham
Thanh Nhat Pham
PLPauline Loupias
Pauline Loupias
ADAlexandra Dassonville‐Klimpt
Alexandra Dassonville‐Klimpt
Pascal SonnetPascal Sonnet
Pascal Sonnet

1 August 2024 in Waste Management
Verified
Journal Article
Open access
ECElisabeth A. Cazier
Elisabeth A. Cazier
Thanh Nhat PhamThanh Nhat Pham
Thanh Nhat Pham
LCLouis Cossus
Louis Cossus
MAMaher Abla
Maher Abla
TITina Ilc
Tina Ilc
PLPhilip Lawrence
Philip Lawrence
Lignocellulosic biomass has a promising role in a circular bioeconomy and may be used to produce valuable molecules for green chemistry. Lignocellulosic biomass, such as food waste, agricultural waste, wood, paper or cardboard, corresponded to 15.7% of all waste produced in Europe in 2020, and has a high potential as a secondary raw material for industrial processes. This review first presents industrial lignocellulosic waste sources, in terms of their composition, quantities and types of lignocellulosic residues. Secondly, the possible high added-value chemicals obtained from transformation of lignocellulosic waste are detailed, as well as their potential for applications in the food industry, biomedical, energy or chemistry sectors, including as sources of polyphenols, enzymes, bioplastic precursors or biofuels. In a third part, various available transformation treatments, such as physical treatments with ultrasound or heat, chemical treatments with acids or bases, and biological treatments with enzymes or microorganisms, are presented. The last part discusses the perspectives of the use of lignocellulosic waste and the fact that decreasing the cost of transformation is one of the major issues for improving the use of lignocellulosic biomass in a circular economy and green chemistry approach, since it is currently often more expensive than petroleum-based counterparts.

1 April 2018 in Drug Discovery Today
Verified
Journal Article
Closed access
Thanh Nhat PhamThanh Nhat Pham
Thanh Nhat Pham
BLBertrand Liagre
Bertrand Liagre
CGCorine Girard-Thernier
Corine Girard-Thernier
CDCéline Demougeot
Céline Demougeot

24 October 2016 in Planta Medica
Verified
Journal Article
Closed access
PDF file
SBSimon Bordage
Simon Bordage
Thanh Nhat PhamThanh Nhat Pham
Thanh Nhat Pham
AZAndy Zedet
Andy Zedet
AGAnne-Sophie Gugglielmetti
Anne-Sophie Gugglielmetti
MNMaude Nappey
Maude Nappey
CGCorine Girard-Thernier
Corine Girard-Thernier
Polyphenols are plant secondary metabolites which possess many positive effects on human health. Although these beneficial effects could be mediated through an increase in nitric oxide synthase activity, little is known regarding the inhibitory effect of polyphenols on mammal arginase, an enzyme which competes with nitric oxide synthase for their common substrate, L-arginine. The aim of the present study was to determine the potential of a series of polyphenols as mammalian arginase inhibitors and to identify some structure-activity relationships. For this purpose, we first developed a simple and cost-effective in vitro colorimetric microplate method using commercially-available mammal bovine liver arginase (b-ARG 1). Among the ten tested polyphenolic compounds [chlorogenic acid, piceatannol, resveratrol, (−)-epicatechin, taxifolin, quercetin, fisetin, caffeic acid, quinic acid, and kaempferol], cholorogenic acid and piceatannol exhibited the highest inhibitory activities (IC50 = 10.6 and 12.1 µM, respectively) but were however less active as (S)-(2-Boronoethyl)-L-cysteine (IC50 = 3.3 µM), used as reference compound. Enzyme kinetic studies showed that both chlorogenic acid and piceatannol are competitive arginase inhibitors. Structural data identified the importance of the caffeoyl (3,4-dihydroxycinnamoyl)-part and of the catechol function in the inhibitory activity of the tested compounds. These results identified chlorogenic acid and piceatannol as two potential core structures for the design of new arginase inhibitors. * Simon Bordage and Thanh-Nhat Pham contributed equally to this work.

Verified
Journal Article
Open access
PDF file
Thanh Nhat PhamThanh Nhat Pham
Thanh Nhat Pham
SBSimon Bordage
Simon Bordage
MPMarc Pudlo
Marc Pudlo
CDCéline Demougeot
Céline Demougeot
Khac-Minh ThaiKhac-Minh Thai
Khac-Minh Thai
CGCorine Girard-Thernier
Corine Girard-Thernier
Arginases are enzymes that are involved in many human diseases and have been targeted for new treatments. Here a series of cinnamides was designed, synthesized and evaluated in vitro and in silico for their inhibitory activity against mammalian arginase. Using a microassay on purified liver bovine arginase (b-ARG I), (E)-N-(2-phenylethyl)-3,4-dihydroxycinnamide, also named caffeic acid phenylamide (CAPA), was shown to be slightly more active than our natural reference inhibitor, chlorogenic acid (IC50 = 6.9 ± 1.3 and 10.6 ± 1.6 µM, respectively) but it remained less active that the synthetic reference inhibitor Nω-hydroxy-nor-l-arginine nor-NOHA (IC50 = 1.7 ± 0.2 µM). Enzyme kinetic studies showed that CAPA was a competitive inhibitor of arginase with Ki = 5.5 ± 1 µM. Whereas the activity of nor-NOHA was retained (IC50 = 5.7 ± 0.6 µM) using a human recombinant arginase I (h-ARG I), CAPA showed poorer activity (IC50 = 60.3 ± 7.8 µM). However, our study revealed that the cinnamoyl moiety and catechol function were important for inhibitory activity. Docking results on h-ARG I demonstrated that the caffeoyl moiety could penetrate into the active-site pocket of the enzyme, and the catechol function might interact with the cofactor Mn2+ and several crucial amino acid residues involved in the hydrolysis mechanism of arginase. The results of this study suggest that 3,4-dihydroxycinnamides are worth being considered as potential mammalian arginase inhibitors, and could be useful for further research on the development of new arginase inhibitors.

12 November 2020 in Molecules
Verified
Journal Article
Open access
PDF file
Edson Roberto da SilvaEdson Roberto da Silva
Edson Roberto da Silva
JCJúlio Abel Alfredo dos Santos Simone Come
Júlio Abel Alfredo dos Santos Simone Come
Simone BrogiSimone Brogi
Simone Brogi
VCVincenzo Calderone
Vincenzo Calderone
GCGiulia Chemi
Giulia Chemi
CMClaudia do Carmo Maquiaveli
Claudia do Carmo Maquiaveli
Caffeic acid and related natural compounds were previously described as Leishmania amazonensis arginase (L-ARG) inhibitors, and against the whole parasite in vitro. In this study, we tested cinnamides that were previously synthesized to target human arginase. The compound caffeic acid phenethyl amide (CAPA), a weak inhibitor of human arginase (IC50 = 60.3 ± 7.8 μM) was found to have 9-fold more potency against L-ARG (IC50 = 6.9 ± 0.7 μM). The other compounds that did not inhibit human arginase were characterized as L-ARG, showing an IC50 between 1.3–17.8 μM, and where the most active was compound 15 (IC50 = 1.3 ± 0.1 μM). All compounds were also tested against L. amazonensis promastigotes, and only the compound CAPA showed an inhibitory activity (IC50 = 80 μM). In addition, in an attempt to gain an insight into the mechanism of competitive L-ARG inhibitors, and their selectivity over mammalian enzymes, we performed an extensive computational investigation, to provide the basis for the selective inhibition of L-ARG for this series of compounds. In conclusion, our results indicated that the compounds based on cinnamoyl or 3,4-hydroxy cinnamoyl moiety could be a promising starting point for the design of potential antileishmanial drugs based on selective L-ARG inhibitors.